Global Antispasmodics Drugs Market Size and Forecast 2024-2033|aiichi Sankyo Company Limited, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Johnson & Johnson Services Inc., Pfizer Inc

The Antispasmodics Drugs by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Antispasmodics Drugs Market:

https://www.thebusinessresearchcompany.com/report/antispasmodics-drugs-global-market-report

According to The Business Research Company’s Antispasmodics Drugs, The antispasmodics drugs market size has grown strongly in recent years. It will grow from $12.69 billion in 2023 to $13.92 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to rising prevalence of spasmodic conditions, advancements in medical research, growing aging population, changing lifestyles, improvements in diagnosis

The antispasmodics drugs market size is expected to see strong growth in the next few years. It will grow to $20.04 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing healthcare expenditure, personalized medicine, global population growth, emerging markets, clinical trials and research. Major trends in the forecast period include expanding indications for antispasmodics, healthcare infrastructure development, advancements in drug development, increasing awareness and diagnosis, preference for non-invasive treatment options.

An increasing elderly population is expected to propel the growth of the antispasmodic drug market going forward. People of 65 years and older are considered to be elderly and are associated with a host of physical and psychological health issues. Antispasmodic drugs are helpful for elderly populations in managing symptoms related to various conditions that can cause muscle spasms or cramping and also could be used for some conditions like irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), interstitial cystitis, and uterine cramping. For instance, in October 2022, according to the World Health Organization (WHO), a Switzerland-based organization responsible for international public health, the global proportion of the population aged 60 and up will rise to 1.4 billion in 2030. The world’s population of persons aged 60 and over will double by 2050 (2.1 billion). The number of people aged 80 or more is predicted to increase substantially by 2050, reaching 426 million. Therefore, an increase in the elderly population will drive the antispasmodic drug market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=9414&type=smp

The antispasmodics drugs market covered in this report is segmented –

1) By Drug: Dicyclomine Hydrochloride, Loperamide Hydrochloride, Other Drugs

2) By Indication: Irritable Bowel Syndrome, Stomach Cramps, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Modes Of Administrations

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmnacy

5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Product innovations are a key trend in gaining popularity in the antispasmodic drugs market. Major companies operating in the antispasmodic drugs market are focused on developing innovative solutions to strengthen their position in the market. For instance, in April 2022, Ardelyx Inc., a US-based biopharmaceutical firm, announced the introduction of IBSRELA, an NHE-3 inhibitor used to treat individuals with irritable bowel syndrome with constipation (IBS-C). The product offers a unique new therapeutic option with a novel mode of action and remarkable effective results to address constipation and numerous abdominal symptoms typical in IBS-C patients, as established in Phase 3 clinical studies.

The antispasmodics drugs market report table of contents includes:

1. Executive Summary

2. Antispasmodics Drugs Market Characteristics

3. Antispasmodics Drugs Market Trends And Strategies

4. Antispasmodics Drugs Market – Macro Economic Scenario

5. Global Antispasmodics Drugs Market Size and Growth

26. South America Antispasmodics Drugs Market

27. Brazil Antispasmodics Drugs Market

28. Middle East Antispasmodics Drugs Market

29. Africa Antispasmodics Drugs Market

30. Antispasmodics Drugs Market Competitive Landscape And Company Profiles

Top Major Players: